An overview of health-related industrial biotechnology in Latin America and the Caribbean
Loading...
Cite
Marques, M. B. (1996). An overview of health-related industrial biotechnology in Latin America and the Caribbean [Journal articles]. https://iris.paho.org/handle/10665.2/27649
Date
1996
Document Number
ISBN
eISBN
ISSN
DOI
Authors
Other Language Versions
Description
There is some uncertainty about the extent to which Latin America and the Caribbean have participated in the advances of health-related industry biotechnology. This articule reviews tha available literature and seeks to provide an overview of the prevailing situation. In general, national governments and multinational agencies have provided most of the health-related biotechnology investments within this region. Efforts to achieve technology transfers, a subject of prime concern, have been developed by a number of programs including the WHO Special Program for Research and Training in Tropical Diseases, the UNDP/UNESCO/UNIDO Regional Biotechnology Program for Latin America and the Caribbean; PAHO's Program for the Regional Development of Biotechnology as Applied to Health; the PAHO/WHO Expanded program on Immunization (EPI); and PAHO's Regional System of Vaccines (SIREVA). Regarding current producction capacity, some succesful efforts have been made to produce a variety of therapeutic products including recombinant and natural interferons, interlukins, insulin, and recombinant streptokinase; but in general the region's current potencial in this area is at best incipient and uncertain. However, the region does not have a limited ability to make diagnostic products and a well-established capacity for vaccine development. Overall, this picture suggests that the region has the potencial to play a small but significant role in health-related biotehcnology
This article will also be published in Spanish in the Bol. Oficina Sanit. Panam. Vol. 121(3), September 1996
This article will also be published in Spanish in the Bol. Oficina Sanit. Panam. Vol. 121(3), September 1996
Notes
Pages
Volume
Replaces
Table of contents
Link to WHO's original document
Link to WHO's original document
Category
Youtube URI
Citation
Status Mendates
Collections
License
Related items
Showing items related by metadata.
Item Panorama de biotecnología industrial em saúde na América Latina e Caribe(1996)There is some uncertainty about the extent to which Latin America and the Caribbean have participated in the advances of health-related industrial biotechnology. This article reviews the available literature and seeks to provide an overview of the prevailing situation. In general, national governments and multinational agencies have provided most of the health-related biotechnology in investments within this region. Efforts to achieve technology transfers, a subject of prime concern, have been developed by a number of programs inclluding the WHO Special Program for Research and Training in Tropical Diseases, the UNDP/UNESCO/UNIDO Regional Biotechnology Program for Latin American and the Caribbean; PAHO's Program for the Regional Development of Biotechnology as Applied to Health; the PAHO/WHO Extended Program on Immunization (EPI); and PAHO's Regional System of Vaccines (SIREVA). Regarding current production capacity some successful efforts have been made to produce a variety of therapeutic products including recombinant and natural interferons, interleukins, insulin, and recombinant streptokinase, but in general, the region's current potential in this areas is at best incipientItem Paving pathways: Brazil’s implementation of a national human papillomavirus immunization campaign(2015)In 2014, Brazil introduced an HPV immunization program for girls 9–13 years of age as part of the Unified Health System’s (SUS) National Immunization Program. The first doses were administered in March 2014; the second ones, in September 2014. In less than 3 months more than 3 million girls received the first dose of quadrivalent HPV vaccine, surpassing the target rate of 80%. This paper examines three elements that may influence the program’s long-term success in Brazil: sustaining effective outreach, managing a large tech¬nology-transfer collaboration, and developing an electronic immunization registry, with a focus on the State of São Paulo. If these three factors are managed, the Government of Brazil is primed to serve as a model of success for other countries interested in implementing a national HPV vaccination program to decrease HPV-related morbidity and mortality.Item Health financing and access to medicines in the Caribbean(PAHO, 2024)For millions of people, including those in the Caribbean region, accessing affordable and high-quality medicines poses significant challenges. These include affordability issues, concerns over the quality and safety of medicines, and inadequate financing for health care, as well as the inappropriate use of essential medicines, weak or limited regulatory systems, and complex procurement and supply chain management processes. The Caribbean region also faces a unique set of challenges, including high levels of public debt and significant informal economies. These factors constrain the capacity of governments to invest in social programs and agendas, including the provision of universal health coverage. At present, public spending on health care in the region is only 3.9% of gross domestic product, well below the 6% target. Consequently, many people must rely on out-of-pocket payments for health care, including medicines. This financial burden creates barriers to accessing health care and can lead to the irrational use of prescription drugs and other medicines. This report offers an initial and concise evaluation of certain health financing aspects that are crucial for accessing medicines in the Caribbean. It also provides a preliminary set of recommendations to guide national and regional efforts to improve the region’s current organization, financing, and provision of medicines. These recommendations aim to tackle the significant challenges highlighted in the report, including those related to system financing, barriers to access, and the financial burden of out-of-pocket costs. Envisioned as an integral part of a broader series of initiatives, this study aims to promote equitable, affordable, and sustainable access to medicines and health technologies by strengthening regulatory frameworks and production capacities, as well as by promoting the rational use of medicines. The publication also aims to be a useful resource for policymakers, health professionals, and other stakeholders in the region and beyond, as they work toward ensuring that everyone in the Caribbean has access to the medicines they need to lead healthy and productive lives, and that the region can achieve sustainable and equitable health financing.Item International Seminar COSALFA 15. Importance of Biotechnology in Livestock Development (Goiania, March 22-23, 1988)(PAHO, 1990)[Introduction] In compliance wit Resolution IV appoved at the XIV Regular Meeting of South American Commission for the Control of Foot-and-Mouth Disease (COSALFA), the Pan American Footh-and-Mouth Disease Center (PANAFTOSA) of the Pan American Health Organization (PAHO/WHO), the Ministry of Agriculture of Brazil and the University of Winsconsin, USA, jointly held the "International Seminar on the Importance of Biotechnology in Livestock Development". The following organizations also lent their cooperation: Secretariat of Agriculture of the State of Goiás, the Goiana Livestock and Agriculture Society, the State of Goiás Agriculture Federation and the Goiana Association of Zebu Raisers.Item Mapping dietary salt/sodium reduction policies and initiatives in the Region of the Americas(PAHO, 2021)The aim of this study was to map existing country policies and initiatives addressing population dietary sodium reduction in the Region of the Americas; to identify policy gaps following what is outlined in the World Health Organization (WHO) “Best Buys” most cost-effective recommendations for the prevention and control of diet-related noncommunicable diseases (NCDs); and to discuss priorities for future work to reduce population salt/sodium intake. We analyzed data from 34 countries in the Region. A review of different databases informed the mapping. Databases included (1) responses from the online Survey on National Initiatives for Salt/Sodium Reduction in the Americas carried out by PAHO in 2016; (2) the databases from the 2017 and 2019 PAHO Country Capacity Surveys for NCDs and Risk Factors; and (3) the repositories of legislation of the PAHO REGULA initiative as of 2018. Research in these databases was complemented by electronic searches on official websites from the ministries of health, education, and agriculture and the library of the national congress in each country. Additionally, when available, government regulatory gazettes were reviewed. National policies that have adopted the most cost-effective interventions for preventing and controlling diet-related NCDs of WHO “Best Buys” included reformulating food products with both voluntary (n=11/34) and mandatory (n=2/34) targets; establishing a supportive environment in public institutions (n=13/34); consumer awareness programs (n=26/34) and behavior-change communication and mass media campaigns (n=(0/34); and implementing front-of-pack labeling (n=5/34). We also found that some countries have implemented regulations that restrict marketing of foods high in salt/sodium to children (n=5/34), or are using nutritional labeling that includes sodium content, either voluntary (n=9/34) or mandatory (n=10/34). However, no country in the Region has implemented taxes on high salt/sodium foods. Based on our review, we concluded that there has been a significant advance in policies to reduce sodium intake in the Region of the Americas in recent years. However, we identified that the level of implementation is quite varied and is challenging to assess. Despite the progress, there remains much work to do on this issue, especially in countries where there is limited or no action yet. Reducing sodium consumption is a cost-effective intervention that can save many lives by preventing and reducing the burden of diet-related NCDs. Therefore, a further call to action is needed for governments to accelerate efforts to meet the 2025 global target of a 30% relative reduction in mean population intake of sodium.